enter passkey to continue
incorrect passkey
Testing as the first step, not the last resort.
Every tumor has a molecular story. Genomic profiling at diagnosis unlocks targeted therapies, predicts treatment response, and identifies hereditary cancer risk for the entire family.
Explore the Evidence → ScrollTumor profiling and germline testing should be standard-of-care at diagnosis -- not ordered after first-line therapy fails, not reserved for late-stage disease, not treated as a last resort.
Comprehensive genomic profiling at diagnosis identifies actionable targets before treatment selection, enabling first-line precision therapy instead of empiric chemotherapy followed by molecular testing only after failure.
More than half of all solid tumors harbor genomic alterations with approved or investigational targeted therapies. Delaying profiling means delaying access to the most effective treatment options available.
Up to 10% of cancers are driven by inherited mutations. Identifying germline risk at the point of cancer diagnosis enables cascade testing that can prevent cancer in at-risk family members through enhanced surveillance and risk-reducing interventions.
Sequential single-gene testing costs more and takes longer than upfront comprehensive panels. One test at diagnosis replaces months of trial-and-error prescribing, reducing total cost of care while improving outcomes.
Comprehensive cancer genomics integrates somatic, germline, pharmacogenomic, and longitudinal monitoring into a unified diagnostic framework.
Comprehensive genomic profiling of the tumor to identify actionable mutations, gene fusions, and biomarkers that guide targeted therapy selection.
Hereditary cancer syndrome testing identifies inherited mutations that inform surgical decisions, surveillance strategies, and family cascade testing.
Predict how patients metabolize chemotherapy agents to optimize dosing, avoid severe toxicity, and select regimens most likely to be effective and tolerable.
Circulating tumor DNA monitoring enables real-time disease tracking without invasive tissue biopsies, detecting recurrence and resistance earlier than imaging.
The data is unambiguous: comprehensive genomic profiling at diagnosis changes care, saves lives, and reduces cost.
A bundled, value-based approach that integrates genomic testing into cancer care from the moment of diagnosis through treatment selection and family risk management.
Oncology referral triggers automatic genomic pathway enrollment. Clinical criteria route to appropriate testing tier.
Somatic tumor profiling, germline panel, and PGx testing ordered as a coordinated bundle at diagnosis.
Results integrated into tumor board review. Targeted therapy selection based on molecular profile, not empiric protocol.
Liquid biopsy for longitudinal monitoring. Germline findings trigger cascade testing to protect at-risk family members.
All testing, counseling, and interpretation bundled into a single care episode with a defined cost -- replacing fragmented, sequential single-gene authorizations.
Diagnostic yield, time-to-targeted-therapy, toxicity avoidance rate, and cascade testing uptake -- all tracked as program KPIs with auditable endpoints.
Upfront comprehensive profiling eliminates sequential testing, reduces trial-and-error prescribing, prevents avoidable toxicity, and accelerates time to effective therapy.